Acute Kidney Injury Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Novartis, AbbVie, Alloksys, Guard Therapeutics, Ocelot Bio

DelveInsight’s “Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Acute Kidney Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Kidney Injury Market Forecast

Some of the key facts of the Acute Kidney Injury Market Report: 

• The Acute Kidney Injury market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The study by Sohaney et al. (2021) and the prior study were both used to compute the stage-specific incident instances of Acute Kidney Injury. The study found that there were 4,263,600 hospitalizations during the investigation period and showed that between 2008 and 2017, there was a slight decline in the frequency of Acute Kidney Injury among hospitalized veterans
• Acute Kidney Injury occurs in 8-22% of all hospital patients, according to a study by Khadzhynov et al. (2019), and it is a common and relevant clinical occurrence. The study examined every instance of Acute Kidney Injury over a 3.5-year period (2014-2017). Stage 1 Acute Kidney Injury occurred in 25,417 cases (13.7%), stage 2 in 8,503 cases (4.6%), and stage 3 in 5881 cases (3.1%) among 185,760 hospitalizations
• Among the seven largest markets, the mortality adjusted incident population of Acute Kidney Injury among hospitalized patients was projected to reach 6,485,000 in 2022
• Compared to the EU4, the UK, Japan, and the US, the US has the greatest incident population of Acute Kidney Injury in hospitalized patients. In hospitalized patients in the United States, the mortality adjusted incident population of Acute Kidney Injury accounted for 2,215,000 in 2022. 1,570,000, 398,000, and 243,000 cases of Stage I, Stage II, and Stage III Acute Kidney Injury, respectively, were reported in the United States in 2022
• In the US, cases among those aged 60 to 84 and 85 and older were highest in 2022. In contrast, the age range of 18 to 59 had the fewest cases. For the age ranges of 18 to 59 years, 60 to 84 years, and 85 years and above, there were 309,000, 995,000, and 906,000 cases in 2022, respectively.
• Key Acute Kidney Injury Companies: Alloksys, Guard Therapeutics, Ocelot Bio, Pharming Technologies, Scios, Inc., Thrasos Innovation, Inc., AbbVie, Quark Pharmaceuticals, Rediscovery Life Sciences, NeuroVive Pharma, MediBeacon, Astellas Pharma, CorMedix, CSPC ZhongQi Pharma, Novartis, and others
• Key Acute Kidney Injury Therapies: bRESCAP, RMC-035 (ROSgard), OCE-205, Conestat alfa (Ruconest®), Neseritide, THR-184, ABT-719, QPI-1002, Suramin, Ciclosporin, MB-102, ASP1128, CRMD-001-Deferiprone, Alprostadil liposome injection, TIN816, and others
• The Acute Kidney Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Kidney Injury pipeline products will significantly revolutionize the Acute Kidney Injury market dynamics.

Acute Kidney Injury Overview

Acute renal failure (ARF), commonly referred to as acute kidney injury (Acute Kidney Injury), is characterized by azotemia that worsens over a period of hours or days with or without oliguria. Acute kidney injury (Acute Kidney Injury) is typically described as a sudden loss in renal function that manifests clinically as a temporary rise in nitrogen waste products as assessed by blood ureanitrogen (BUN) and serum creatinine levels over the course of a few hours to many weeks.

Get a Free sample for the Acute Kidney Injury Market Report 

https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market

Acute Kidney Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Kidney Injury Epidemiology Segmentation:

The Acute Kidney Injury market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Acute Kidney Injury
• Prevalent Cases of Acute Kidney Injury by severity
• Gender-specific Prevalence of Acute Kidney Injury
• Diagnosed Cases of Episodic and Chronic Acute Kidney Injury

Download the report to understand which factors are driving Acute Kidney Injury epidemiology trends @ Acute Kidney Injury Epidemiology Forecast

Acute Kidney Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Kidney Injury market or expected to get launched during the study period. The analysis covers Acute Kidney Injury market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Kidney Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Kidney Injury Therapies and Key Companies

• bRESCAP: Alloksys
• RMC-035 (ROSgard): Guard Therapeutics
• OCE-205: Ocelot Bio
• Conestat alfa (Ruconest®): Pharming Technologies
• Neseritide: Scios, Inc.
• THR-184: Thrasos Innovation, Inc.
• ABT-719: AbbVie
• QPI-1002: Quark Pharmaceuticals
• Suramin: Rediscovery Life Sciences
• Ciclosporin: NeuroVive Pharma
• MB-102: MediBeacon
• ASP1128: Astellas Pharma
• CRMD-001-Deferiprone: CorMedix
• Alprostadil liposome injection: CSPC ZhongQi Pharma
• TIN816: Novartis

Discover more about therapies set to grab major Acute Kidney Injury market share @ Acute Kidney Injury Treatment Market

Acute Kidney Injury Market Strengths

• The pipeline of Acute Kidney Injury is quite robust with diverse products strengthening the upcoming market.
• The treatment related adverse events are very nominal resulting into effective treatment options

Acute Kidney Injury Market Opportunities

• Several biomarkers such as NGAL, Cystatin-C, etc. are being tried and tested to diagnose Acute Kidney Injury. Validation of these new biomarkers could provide additional tools to detect the onset and severity of kidney injury

Scope of the Acute Kidney Injury Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acute Kidney Injury Companies: Alloksys, Guard Therapeutics, Ocelot Bio, Pharming Technologies, Scios, Inc., Thrasos Innovation, Inc., AbbVie, Quark Pharmaceuticals, Rediscovery Life Sciences, NeuroVive Pharma, MediBeacon, Astellas Pharma, CorMedix, CSPC ZhongQi Pharma, Novartis, and others
• Key Acute Kidney Injury Therapies: bRESCAP, RMC-035 (ROSgard), OCE-205, Conestat alfa (Ruconest®), Neseritide, THR-184, ABT-719, QPI-1002, Suramin, Ciclosporin, MB-102, ASP1128, CRMD-001-Deferiprone, Alprostadil liposome injection, TIN816, and others
• Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
• Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Acute Kidney Injury Unmet Needs, KOL’s views, Analyst’s views, Acute Kidney Injury Market Access and Reimbursement 

To know more about Acute Kidney Injury companies working in the treatment market, visit @ Acute Kidney Injury Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Acute Kidney Injury Market Report Introduction

2. Executive Summary for Acute Kidney Injury

3. SWOT analysis of Acute Kidney Injury

4. Acute Kidney Injury Patient Share (%) Overview at a Glance

5. Acute Kidney Injury Market Overview at a Glance

6. Acute Kidney Injury Disease Background and Overview

7. Acute Kidney Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Kidney Injury 

9. Acute Kidney Injury Current Treatment and Medical Practices

10. Acute Kidney Injury Unmet Needs

11. Acute Kidney Injury Emerging Therapies

12. Acute Kidney Injury Market Outlook

13. Country-Wise Acute Kidney Injury Market Analysis (2019–2032)

14. Acute Kidney Injury Market Access and Reimbursement of Therapies

15. Acute Kidney Injury Market Drivers

16. Acute Kidney Injury Market Barriers

17.  Acute Kidney Injury Appendix

18. Acute Kidney Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services